Prudential PLC Increases Stock Position in Zoetis Inc. $ZTS

Prudential PLC boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 1.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 168,150 shares of the company’s stock after buying an additional 2,886 shares during the quarter. Prudential PLC’s holdings in Zoetis were worth $26,223,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Nova Wealth Management Inc. purchased a new position in Zoetis during the first quarter worth approximately $25,000. 1248 Management LLC acquired a new position in shares of Zoetis during the 1st quarter worth approximately $27,000. Saudi Central Bank acquired a new position in shares of Zoetis during the 1st quarter worth approximately $29,000. REAP Financial Group LLC lifted its position in shares of Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after buying an additional 131 shares in the last quarter. Finally, NewSquare Capital LLC grew its stake in Zoetis by 69.1% in the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

Shares of NYSE ZTS opened at $116.96 on Thursday. The firm has a 50-day simple moving average of $138.98 and a 200-day simple moving average of $150.66. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The stock has a market capitalization of $51.54 billion, a price-to-earnings ratio of 20.13, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $181.85.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same period in the previous year, the business posted $1.58 earnings per share. Zoetis’s quarterly revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a $0.50 dividend. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. Zoetis’s dividend payout ratio is 33.67%.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. JPMorgan Chase & Co. cut their price target on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Piper Sandler lifted their target price on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Stifel Nicolaus decreased their price target on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research note on Tuesday. Finally, BTIG Research cut their price objective on Zoetis from $200.00 to $160.00 and set a “buy” rating for the company in a research note on Wednesday, November 12th. Six research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, Zoetis presently has a consensus rating of “Moderate Buy” and an average target price of $178.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.